Epidemiology of head and neck cancer, Surg Oncol Clin, vol.24, pp.379-396, 2015. ,
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients, Radiother Oncol, vol.92, pp.4-14, 2009. ,
Head and neck cancer: changing epidemiology, diagnosis, and treatment, Mayo Clin Proc, vol.83, pp.489-501, 2008. ,
Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med, vol.359, pp.1116-1127, 2008. ,
Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study, J Clin Oncol, vol.10, pp.1245-1251, 1992. ,
Molecular profiling of head and neck squamous cell carcinoma, Head Neck, vol.38, pp.1625-1638, 2016. ,
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximabinduced rash and survival, Lancet Oncol, vol.11, issue.09, pp.70311-70311, 2010. ,
Treatments and costs for recurrent and/or metastatic squamous cell carcinoma of the head and neck in the Netherlands, Eur Arch Otorhinolaryngol, vol.273, pp.455-464, 2016. ,
A 3?-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, Ann Oncol, vol.25, pp.2230-2236, 2014. ,
A SNP in a let-7 microRNA complementary site in the KRAS 3?UTR increases non-small cell lung cancer risk, Cancer Res, vol.68, pp.8535-8540, 2008. ,
A let-7 microRNA polymorphism in the KRAS 3?-UTR is prognostic in oropharyngeal cancer, Cancer Epidemiol, vol.38, pp.591-598, 2014. ,
A let-7 microRNAbinding site polymorphism in the KRAS 3? UTR is associated with reduced survival in oral cancers, Carcinogenesis, vol.30, pp.1003-1007, 2009. ,
The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial, JAMA Oncol, vol.3, pp.483-491, 2017. ,
The EXTREME regimen for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): treatment outcome in a single institution cohort, Acta Oncol, vol.54, pp.1071-1075, 2015. ,
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a retrospective study in a single comprehensive European cancer institution, PloS One, vol.9, 2014. ,
Cetuximab-based therapy in recurrent/metastatic head and neck squamous cell carcinoma: experience from an area in which betel nut chewing is popular, J Chin Med Assoc, vol.73, issue.10, pp.70064-70066, 2010. ,
Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial, Jpn J Clin Oncol, vol.43, pp.524-531, 2013. ,
Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: a randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen, BMC Cancer, vol.16, 2016. ,
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck, J Clin Oncol, vol.23, pp.5578-5587, 2005. ,
The involvement of Kras gene 3?-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis, OncoTargets Ther, vol.7, pp.1487-1496, 2014. ,
rs61764370 polymorphism of Kras and risk of cancer in Caucasian population: a meta-analysis, J Cancer Res Ther, vol.12, p.699, 2016. ,
A let-7 microRNA SNP in the KRAS 3?UTR is prognostic in early-stage colorectal cancer, Clin Cancer Res, vol.17, pp.7723-7731, 2011. ,
Genetic modulation of the Let-7 microRNA binding to KRAS 3?-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan, Pharmacogenom J, vol.10, pp.458-464, 2010. ,
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer, Gynecol Oncol, vol.141, pp.386-401, 2016. ,
A 3?-untranslated region KRAS variant and triple-negative breast cancer: a casecontrol and genetic analysis, Lancet Oncol, vol.12, issue.11, pp.70044-70048, 2011. ,
Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels, Hum Mutat, vol.35, pp.208-214, 2014. ,